Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.

Tan YC, Srivastava S, Won BM, Kanteti R, Arif Q, Husain AN, Li H, Vigneswaran WT, Pang KM, Kulkarni P, Sattler M, Vaidehi N, Mambetsariev I, Kindler HL, Wheeler DL, Salgia R.

Oncogenesis. 2019 Sep 4;8(9):49. doi: 10.1038/s41389-019-0159-6.

2.

The Mitochondrion as an Emerging Therapeutic Target in Cancer.

Roth KG, Mambetsariev I, Kulkarni P, Salgia R.

Trends Mol Med. 2019 Jul 18. pii: S1471-4914(19)30171-6. doi: 10.1016/j.molmed.2019.06.009. [Epub ahead of print] Review.

PMID:
31327706
3.

Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.

Mambetsariev I, Mirzapoiazova T, Lennon F, Jolly MK, Li H, Nasser MW, Vora L, Kulkarni P, Batra SK, Salgia R.

J Clin Med. 2019 Jul 16;8(7). pii: E1038. doi: 10.3390/jcm8071038.

4.

Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.

Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R.

Am J Clin Oncol. 2019 Apr;42(4):337-344. doi: 10.1097/COC.0000000000000508.

PMID:
30741758
5.

The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer.

Hewelt B, Li H, Jolly MK, Kulkarni P, Mambetsariev I, Salgia R.

Bioinformatics. 2019 Aug 15;35(16):2738-2748. doi: 10.1093/bioinformatics/bty1021.

6.

Heuristic value-based framework for lung cancer decision-making.

Mambetsariev I, Pharaon R, Nam A, Knopf K, Djulbegovic B, Villaflor VM, Vokes EE, Salgia R.

Oncotarget. 2018 Jul 6;9(52):29877-29891. doi: 10.18632/oncotarget.25643. eCollection 2018 Jul 6.

7.

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.

Salgia R, Mambetsariev I, Hewelt B, Achuthan S, Li H, Poroyko V, Wang Y, Sattler M.

Oncotarget. 2018 May 25;9(40):26226-26242. doi: 10.18632/oncotarget.25360. eCollection 2018 May 25. Review.

8.

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients.

Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, Husain A, Vokes EE, Wheeler DL, Salgia R.

Oncotarget. 2018 Apr 13;9(28):19793-19806. doi: 10.18632/oncotarget.24857. eCollection 2018 Apr 13.

9.

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.

Mambetsariev I, Vora L, Yu KW, Salgia R.

BMC Cancer. 2018 Mar 21;18(1):314. doi: 10.1186/s12885-018-4222-z.

10.

The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.

Amanam I, Gupta R, Mambetsariev I, Salgia R.

Future Oncol. 2018 Aug;14(19):1897-1908. doi: 10.2217/fon-2017-0545. Epub 2018 Feb 16.

PMID:
29451020
11.

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience.

Yuan Y, Yost SE, Yim J, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J.

Oncotarget. 2017 Sep 22;8(37):62817. doi: 10.18632/oncotarget.20632. eCollection 2017 Sep 22.

12.

Value-Based Medicine and Integration of Tumor Biology.

Brooks GA, Bosserman LD, Mambetsariev I, Salgia R.

Am Soc Clin Oncol Educ Book. 2017;37:833-840. doi: 10.14694/EDBK_175519. Review.

PMID:
28561700
13.

Genomic mutation-driven metastatic breast cancer therapy: a single center experience.

Yuan Y, Yost SE, Yim J, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J.

Oncotarget. 2017 Apr 18;8(16):26414-26423. doi: 10.18632/oncotarget.14476. Erratum in: Oncotarget. 2017 Sep 22;8(37):62817. Yim, John [added].

14.

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.

Won B, Mambetsariev I, Salgia R.

BMC Cancer. 2016 Aug 2;16:568. doi: 10.1186/s12885-016-2636-z.

15.

Modulation of Endothelial Inflammation by Low and High Magnitude Cyclic Stretch.

Tian Y, Gawlak G, O'Donnell JJ 3rd, Mambetsariev I, Birukova AA.

PLoS One. 2016 Apr 29;11(4):e0153387. doi: 10.1371/journal.pone.0153387. eCollection 2016.

16.

Role of microtubules in attenuation of PepG-induced vascular endothelial dysfunction by atrial natriuretic peptide.

Tian Y, Mambetsariev I, Sarich N, Meng F, Birukova AA.

Biochim Biophys Acta. 2015 Jan;1852(1):104-19. doi: 10.1016/j.bbadis.2014.10.012. Epub 2014 Oct 27.

17.

Attenuation of lipopolysaccharide-induced lung vascular stiffening by lipoxin reduces lung inflammation.

Meng F, Mambetsariev I, Tian Y, Beckham Y, Meliton A, Leff A, Gardel ML, Allen MJ, Birukov KG, Birukova AA.

Am J Respir Cell Mol Biol. 2015 Feb;52(2):152-61. doi: 10.1165/rcmb.2013-0468OC.

18.

Stiffness-activated GEF-H1 expression exacerbates LPS-induced lung inflammation.

Mambetsariev I, Tian Y, Wu T, Lavoie T, Solway J, Birukov KG, Birukova AA.

PLoS One. 2014 Apr 16;9(4):e92670. doi: 10.1371/journal.pone.0092670. eCollection 2014.

Supplemental Content

Loading ...
Support Center